France leads Europe: reimburses anti-obesity drugs from June 15
France becomes the first country in Europe to reimburse anti-obesity drugs, with coverage set to begin on 15 June, Health Minister Stéphanie Rist announced on Thursday. The move applies to weight-loss medications, including GLP-1 receptor agonists like Ozempic and Zepbound, which will now be partially or fully covered under the national health insurance system, according to reports by *Euronews* and *Digi24* .
The decision follows growing evidence of broader health benefits linked to these drugs. Research presented at the American Society of Clinical Oncology (ASCO) conference highlights their potential anti-cancer effects, with studies showing reduced tumor progression in patients taking GLP-1 medications and improved survival rates among breast cancer patients, *Courrier International* reports . France’s reimbursement policy positions it at the forefront of a shifting European approach to obesity treatment, as other nations, including the U.S., expand coverage for similar drugs—CVS, for example, recently reinstated coverage for Eli Lilly’s Zepbound .
The policy reflects France’s broader push to integrate innovative therapies into public health frameworks, though it arrives amid ongoing debates over cost and accessibility. With obesity rates rising across Europe, France’s model may set a precedent for other EU member states grappling with the financial and medical implications of long-term weight-loss drug use.





